Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 8/20 | 0.36 |
| ▸ | CA9 | Q16790 | 8/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10529566 | 0.91 | HSD17B3 (0.38) | NR4A2CA12CA9L3MBTL1MAPT | |
| SCHEMBL7216486 | 0.84 | CA12 (0.41) | CA12CA9NPC1RAB9AATM | |
| SCHEMBL7218351 | 0.83 | CA12 (0.52) | CA12CA9NPC1RAB9AATM | |
| SCHEMBL7616077 | 0.82 | ALDH1A1 (0.42) | NPC1RAB9AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL7712649 | 0.81 | RAB9A (0.46) | CA12CA9NPC1RAB9AATM | |
| SCHEMBL7714645 | 0.80 | PNMT (0.40) | CA12CA9NPC1RAB9AL3MBTL1 | |
| SCHEMBL12913025 | 0.79 | CA12 (0.40) | NR4A2CA12CA9L3MBTL1SLC6A3 | |
| SCHEMBL7378104 | 0.79 | CA12 (0.48) | CA12CA9NPC1RAB9AL3MBTL1 | |
| SCHEMBL3459411 | 0.79 | GAA (0.38) | NR4A2CA12CA9MAPTSLC6A3 | |
| SCHEMBL3459409 | 0.79 | GAA (0.38) | NR4A2CA12CA9MAPTSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604024-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-23 | — | — | US | disclosed |
| WO-2012162330-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS FOR THE PRODUCTION OF BETA-AMYLOID | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162330-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS FOR THE PRODUCTION OF BETA-AMYLOID | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6413947-B1 | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6376536-B1 | VIRICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| US-6096780-A | ANTIVIRAL COMPOUND USEFUL FOR TREATING HIV VIRUSES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131051-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, SCN2B | NR4A2 13/4885CA12 1317/4885CA9 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.